Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Amgen's stock plunges after early trial data suggests its weight loss drug, MariTide, may decrease bone density.
Amgen's stock dropped over 7% after data from an early-stage trial of its experimental weight loss drug, MariTide, showed a potential 4% decrease in bone mineral density over 12 weeks.
While some analysts see this as a safety risk, others argue it's an overreaction and call for more data.
MariTide aims to be taken monthly, unlike weekly treatments from competitors.
Wall Street awaits phase two trial results expected by year-end.
14 Articles
El stock de Amgen se hunde después de que los datos de los primeros ensayos sugieren que su fármaco para bajar de peso, MariTide, puede disminuir la densidad ósea.